Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Preferred Stock Liabilities (2022 - 2023)

TriSalus Life Sciences' Preferred Stock Liabilities history spans 2 years, with the latest figure at $12.0 million for Q2 2023.

  • For Q2 2023, Preferred Stock Liabilities fell 95.18% year-over-year to $12.0 million; the TTM value through Jun 2023 reached $12.0 million, down 95.18%, while the annual FY2022 figure was $164.0 million, N/A changed from the prior year.
  • Preferred Stock Liabilities reached $12.0 million in Q2 2023 per TLSIW's latest filing, down from $20.2 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $250.0 million in Q2 2022 to a low of $12.0 million in Q2 2023.